Last 7 days
5.8%
Last 30 days
-4.3%
Last 90 days
-7.9%
Trailing 12 Months
22.3%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 129.1B | 26.3B | 4.25% | 2.73% | 19.7 | 4.9 | 1.32% | 11.18% |
GILD | 103.5B | 27.3B | 2.11% | 42.30% | 22.53 | 3.79 | -0.09% | -26.23% |
MRNA | 59.1B | 19.3B | 6.22% | -15.71% | 7.07 | 3.07 | 4.29% | -31.47% |
BIIB | 40.1B | 10.2B | 1.95% | 30.37% | 13.18 | 3.95 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.6B | 1.5B | -3.77% | 7.31% | 61.97 | 6.43 | 31.34% | 72.43% |
DNLI | 3.0B | 108.5M | -19.30% | -32.38% | -9.14 | 27.47 | 122.90% | -12.19% |
BBIO | 2.5B | 107.9M | 50.18% | 65.38% | -5.15 | 23.14 | 54.84% | 17.36% |
BEAM | 2.2B | 60.9M | -25.07% | -49.29% | -7.55 | 35.83 | 17.51% | 22.00% |
SMALL-CAP | ||||||||
RCUS | 1.3B | 112.0M | -4.12% | -47.72% | -4.77 | 11.36 | -70.76% | -603.77% |
REPL | 989.9M | 7.0M | -20.18% | 2.82% | -6.31 | 141.2 | 131.81% | -45.39% |
NVAX | 596.3M | 2.0B | -28.83% | -91.18% | -0.91 | 0.3 | 72.89% | 62.27% |
FATE | 515.7M | 96.3M | -13.40% | -86.70% | -1.83 | 5.35 | 72.44% | -32.79% |
SGMO | 283.5M | 111.3M | -44.26% | -71.33% | -1.47 | 2.55 | 0.54% | -7.86% |
VXRT | 101.5M | 107.0K | -2.91% | -84.84% | -0.94 | 949.05 | -88.00% | -52.91% |
IBIO | 25.7M | - | 64.06% | -80.69% | -0.32 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 4.4% | 2,096 | 2,008 | 1,912 | 1,880 | 1,846 |
Cost Of Revenue | 1.6% | 484 | 476 | 463 | 467 | 471 |
S&GA Expenses | 3.4% | 854 | 826 | 792 | 780 | 759 |
R&D Expenses | 1.8% | 650 | 638 | 638 | 641 | 629 |
Costs and Expenses | 2.4% | 1,946 | 1,900 | 1,854 | 1,850 | 1,929 |
EBITDA | 42.1% | 268 | 188 | 146 | 127 | - |
EBITDA Margin | 36.1% | 0.13* | 0.09* | 0.08* | 0.07* | - |
Earnings Before Taxes | 48.7% | 150 | 101 | 56.00 | 36.00 | -75.35 |
EBT Margin | 42.5% | 0.07* | 0.05* | 0.03* | 0.02* | - |
Interest Expenses | -1.4% | 16.00 | 16.00 | 15.00 | 15.00 | 15.00 |
Net Income | 68.7% | 142 | 84.00 | 54.00 | 39.00 | -64.08 |
Net Income Margin | 61.6% | 0.07* | 0.04* | 0.03* | 0.02* | - |
Free Cahsflow | -17.1% | 55.00 | 66.00 | 16.00 | 47.00 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 1.8% | 6,375 | 6,264 | 6,146 | 6,063 | 6,005 |
Current Assets | 2.6% | 2,751 | 2,683 | 2,518 | 2,394 | 2,274 |
Cash Equivalents | -4.9% | 725 | 762 | 620 | 605 | 587 |
Inventory | 6.5% | 894 | 839 | 802 | 786 | 777 |
Net PPE | 2.0% | 1,073 | 1,052 | 1,049 | 1,040 | 1,035 |
Goodwill | 0% | 196 | 196 | 196 | 196 | 196 |
Liabilities | 4.5% | 1,772 | 1,696 | 1,641 | 1,671 | 1,739 |
Current Liabilities | 13.0% | 589 | 521 | 465 | 490 | 546 |
Shareholder's Equity | 0.8% | 4,603 | 4,569 | 4,500 | 4,391 | 4,266 |
Retained Earnings | 0.0% | -789 | -788 | -777 | -804 | -930 |
Additional Paid-In Capital | 1.3% | 5,405 | 5,336 | 5,273 | 5,206 | 5,192 |
Accumulated Depreciation | 2.7% | 782 | 762 | 741 | 721 | - |
Shares Outstanding | 0.2% | 186 | 186 | 185 | 185 | 184 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -2.4% | 176 | 180 | 119 | 146 | 305 |
Share Based Compensation | 1.5% | 196 | 193 | 188 | 196 | 197 |
Cashflow From Investing | 3.4% | -20.03 | -20.74 | -117 | -207 | -366 |
Cashflow From Financing | -23.3% | -18.65 | -15.12 | -23.69 | -0.96 | -0.05 |
Buy Backs | NaN% | 0.00 | 0.00 | - | - | - |
64.6%
30%
18.5%
Y-axis is the maximum loss one would have experienced if Biomarin Pharmaceutical was unfortunately bought at previous high price.
4.5%
2.1%
3.3%
4.9%
FIve years rolling returns for Biomarin Pharmaceutical.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-27 | Neo Ivy Capital Management | sold off | -100 | -68,000 | - | -% |
2023-03-23 | MetLife Investment Management, LLC | added | 0.47 | 72,924 | 394,711 | -% |
2023-03-17 | American Portfolios Advisors | reduced | -21.96 | -9,058 | 35,858 | -% |
2023-03-15 | B. Riley Wealth Advisors, Inc. | new | - | 271,351 | 271,351 | 0.01% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | 1,486 | 8,486 | -% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 2.7 | 15,822,600 | 78,168,600 | 0.09% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -48.3 | -31,873,000 | 54,541,000 | 0.27% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | unchanged | - | 1,175 | 5,175 | -% |
2023-02-28 | Voya Investment Management LLC | added | 5.08 | 1,750,370 | 7,937,370 | 0.01% |
2023-02-24 | National Pension Service | reduced | -4.35 | 3,893,290 | 27,661,000 | 0.05% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | dodge & cox | 7.7% | 14,383,663 | SC 13G/A | |
Feb 13, 2023 | capital research global investors | 3.0% | 5,651,001 | SC 13G/A | |
Feb 09, 2023 | primecap management co/ca/ | 9.46% | 17,580,859 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.34% | 17,365,080 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 8.2% | 15,206,690 | SC 13G/A | |
Mar 11, 2022 | blackrock inc. | 7.6% | 14,021,292 | SC 13G/A | |
Feb 14, 2022 | dodge & cox | 8.1% | 14,825,049 | SC 13G/A | |
Feb 10, 2022 | primecap management co/ca/ | 9.7% | 17,804,780 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 8.91% | 16,351,031 | SC 13G/A | |
Feb 08, 2022 | blackrock inc. | 7.6% | 14,021,292 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 23.66 -75.67% | 28.40 -70.79% | 38.90 -60.00% | 49.62 -48.97% | 60.19 -38.10% |
Current Inflation | 22.20 -77.17% | 26.25 -73.00% | 35.14 -63.86% | 44.14 -54.61% | 53.00 -45.50% |
Very High Inflation | 20.39 -79.03% | 23.65 -75.68% | 30.70 -68.43% | 37.76 -61.17% | 44.70 -54.03% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 17, 2023 | 4 | Insider Trading | |
Mar 17, 2023 | 4 | Insider Trading | |
Mar 17, 2023 | 4 | Insider Trading | |
Mar 17, 2023 | 4 | Insider Trading | |
Mar 17, 2023 | 4 | Insider Trading | |
Mar 17, 2023 | 4 | Insider Trading | |
Mar 17, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 144 | Notice of Insider Sale Intent | |
Mar 10, 2023 | 144 | Notice of Insider Sale Intent |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-16 | Mueller Brian | sold (taxes) | -371,118 | 93.41 | -3,973 | evp, chief financial officer |
2023-03-16 | Davis George Eric | sold (taxes) | -1,864,180 | 93.41 | -19,957 | evp, chief legal officer |
2023-03-16 | Ajer Jeffrey Robert | sold (taxes) | -1,915,840 | 93.41 | -20,510 | evp, chief commercial officer |
2023-03-16 | BIENAIME JEAN JACQUES | sold (taxes) | -8,278,270 | 93.41 | -88,623 | chief executive officer |
2023-03-16 | FUCHS HENRY J | sold (taxes) | -3,362,760 | 93.41 | -36,000 | president, worldwide r&d |
2023-03-15 | BIENAIME JEAN JACQUES | acquired | - | - | 36,100 | chief executive officer |
2023-03-15 | Davis George Eric | acquired | - | - | 8,900 | evp, chief legal officer |
2023-03-15 | Burkhart Erin | acquired | - | - | 3,760 | gvp, chief accounting officer |
2023-03-15 | FUCHS HENRY J | sold (taxes) | -421,064 | 87.74 | -4,799 | president, worldwide r&d |
2023-03-15 | Ajer Jeffrey Robert | acquired | - | - | 10,110 | evp, chief commercial officer |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | [1] | |||||||
REVENUES: | ||||||||||
Total revenues | $ 2,096,039 | $ 1,846,275 | $ 1,860,455 | |||||||
OPERATING EXPENSES: | ||||||||||
Cost of sales | 483,669 | 470,515 | 524,272 | |||||||
Research and development | 649,606 | 628,793 | 628,116 | |||||||
Selling, general and administrative | 854,009 | 759,375 | 737,669 | |||||||
Intangible asset amortization and contingent consideration | 67,193 | 69,933 | 66,658 | |||||||
Gain on sale of nonfinancial assets, net | (108,000) | 0 | (52,820) | |||||||
Total operating expenses | 1,946,477 | 1,928,616 | 1,903,895 | |||||||
INCOME (LOSS) FROM OPERATIONS | 149,562 | (82,341) | (43,440) | |||||||
Interest income | 18,034 | 10,482 | 16,610 | |||||||
Interest expense | (15,970) | (15,337) | (29,309) | |||||||
Other income (expense), net | (2,050) | 11,846 | 7,142 | |||||||
INCOME (LOSS) BEFORE INCOME TAXES | 149,576 | (75,350) | (48,997) | |||||||
Provision for (benefit from) income taxes | 8,015 | (11,270) | (903,026) | |||||||
NET INCOME (LOSS) | $ 141,561 | $ (64,080) | $ 854,029 | [2],[3] | ||||||
EARNINGS (LOSS) PER SHARE, BASIC (in dollars per share) | $ 0.76 | $ (0.35) | $ 4.72 | |||||||
EARNINGS (LOSS) PER SHARE, DILUTED (in dollars per share) | $ 0.75 | $ (0.35) | $ 4.50 | |||||||
Weighted-average common shares outstanding, basic (in shares) | 185,266 | 182,852 | 180,804 | |||||||
Weighted average common shares outstanding, diluted (in shares) | 188,963 | 182,852 | 191,678 | |||||||
Net product revenues | ||||||||||
REVENUES: | ||||||||||
Total revenues | $ 2,042,025 | $ 1,783,498 | $ 1,805,861 | |||||||
Royalty and other revenues | ||||||||||
REVENUES: | ||||||||||
Total revenues | $ 54,014 | $ 62,777 | $ 54,594 | |||||||
|
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 | [1] | ||
---|---|---|---|---|---|
Current assets: | |||||
Cash and cash equivalents | $ 724,531 | $ 587,276 | |||
Short-term investments | 567,006 | 426,599 | |||
Accounts receivable, net | 461,316 | 373,399 | |||
Inventory | 894,083 | 776,669 | |||
Other current assets | 104,521 | 110,442 | |||
Total current assets | 2,751,457 | 2,274,385 | |||
Noncurrent assets: | |||||
Long-term investments | 333,835 | 507,793 | |||
Property, plant and equipment, net | 1,073,366 | 1,035,461 | |||
Intangible assets, net | 338,569 | 388,652 | |||
Goodwill | 196,199 | 196,199 | |||
Deferred tax assets | 1,505,412 | 1,450,161 | |||
Other assets | 176,236 | 152,121 | |||
Total assets | 6,375,074 | 6,004,772 | |||
Current liabilities: | |||||
Accounts payable and accrued liabilities | 572,959 | 498,265 | |||
Short-term contingent consideration | 15,925 | 48,232 | |||
Total current liabilities | 588,884 | 546,497 | |||
Noncurrent liabilities: | |||||
Long-term convertible debt, net | 1,083,019 | 1,079,077 | |||
Long-term contingent consideration | 0 | 15,167 | |||
Other long-term liabilities | 100,015 | 98,362 | |||
Total liabilities | 1,771,918 | 1,739,103 | |||
Stockholders’ equity: | |||||
Common stock, $0.001 par value: 500,000,000 shares authorized; 186,250,719 and 183,912,514 shares issued and outstanding, respectively | 186 | 184 | |||
Additional paid-in capital | 5,404,895 | 5,191,502 | |||
Company common stock held by the Nonqualified Deferred Compensation Plan | (8,859) | (9,689) | |||
Accumulated other comprehensive income (loss) | (3,867) | 14,432 | |||
Accumulated deficit | (789,199) | (930,760) | |||
Total stockholders’ equity | 4,603,156 | 4,265,669 | |||
Total liabilities and stockholders’ equity | $ 6,375,074 | $ 6,004,772 | |||
|